Cargando…
Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD
BACKGROUND: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care. OBJECTIVE: To determine whether barriers to the use of pharmacotherapy according to practice guid...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155154/ https://www.ncbi.nlm.nih.gov/pubmed/25214921 |
_version_ | 1782333546276323328 |
---|---|
author | Price, Lea Billups, Sarah J. Rice, Melissa A. Hartsfield, Cynthia |
author_facet | Price, Lea Billups, Sarah J. Rice, Melissa A. Hartsfield, Cynthia |
author_sort | Price, Lea |
collection | PubMed |
description | BACKGROUND: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care. OBJECTIVE: To determine whether barriers to the use of pharmacotherapy according to practice guidelines are related primarily to patient or prescriber factors. METHODS: Retrospective cohort study. Members of a health maintenance organization identified as having spirometry-defined COPD ranging from stage II to IV. Electronic medical records were reviewed for documentation of the following: 1) patient affordability issues, 2) history of an adverse drug reaction, 3) history of inefficacy to therapy, and 4) prescription history. RESULTS: A total of 111 medical records were reviewed. There were 51% of patients who had not filled medications that had been prescribed in accordance with guidelines and 43% did not have the guideline recommended medications prescribed in the previous year. Only 4% and 2% of patients had documented inefficacy and affordability issues, respectively. There were no reported cases of adverse drug reactions. CONCLUSIONS: This study provides insight to the acceptance of COPD treatment recommendations by patients and providers. Further research is needed to design interventions to reduce barriers and optimize COPD treatment. |
format | Online Article Text |
id | pubmed-4155154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Centro de Investigaciones y Publicaciones Farmaceuticas |
record_format | MEDLINE/PubMed |
spelling | pubmed-41551542014-09-11 Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD Price, Lea Billups, Sarah J. Rice, Melissa A. Hartsfield, Cynthia Pharm Pract (Granada) Original Research BACKGROUND: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care. OBJECTIVE: To determine whether barriers to the use of pharmacotherapy according to practice guidelines are related primarily to patient or prescriber factors. METHODS: Retrospective cohort study. Members of a health maintenance organization identified as having spirometry-defined COPD ranging from stage II to IV. Electronic medical records were reviewed for documentation of the following: 1) patient affordability issues, 2) history of an adverse drug reaction, 3) history of inefficacy to therapy, and 4) prescription history. RESULTS: A total of 111 medical records were reviewed. There were 51% of patients who had not filled medications that had been prescribed in accordance with guidelines and 43% did not have the guideline recommended medications prescribed in the previous year. Only 4% and 2% of patients had documented inefficacy and affordability issues, respectively. There were no reported cases of adverse drug reactions. CONCLUSIONS: This study provides insight to the acceptance of COPD treatment recommendations by patients and providers. Further research is needed to design interventions to reduce barriers and optimize COPD treatment. Centro de Investigaciones y Publicaciones Farmaceuticas 2007 2007-06-18 /pmc/articles/PMC4155154/ /pubmed/25214921 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Price, Lea Billups, Sarah J. Rice, Melissa A. Hartsfield, Cynthia Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD |
title | Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD |
title_full | Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD |
title_fullStr | Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD |
title_full_unstemmed | Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD |
title_short | Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD |
title_sort | investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of copd |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155154/ https://www.ncbi.nlm.nih.gov/pubmed/25214921 |
work_keys_str_mv | AT pricelea investigationofbarrierstoclinicalpracticeguidelinerecommendedpharmacotherapyinthetreatmentofcopd AT billupssarahj investigationofbarrierstoclinicalpracticeguidelinerecommendedpharmacotherapyinthetreatmentofcopd AT ricemelissaa investigationofbarrierstoclinicalpracticeguidelinerecommendedpharmacotherapyinthetreatmentofcopd AT hartsfieldcynthia investigationofbarrierstoclinicalpracticeguidelinerecommendedpharmacotherapyinthetreatmentofcopd |